AXSOME THERAPEUTICS INC's ticker is AXSM and the CUSIP is 05464T104. A total of 172 filers reported holding AXSOME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $362,617 | -14.5% | 5,189 | -12.1% | 0.00% | 0.0% |
| Q2 2023 | $424,170 | -0.4% | 5,902 | -14.5% | 0.00% | 0.0% |
| Q1 2023 | $425,802 | +8.4% | 6,904 | +35.5% | 0.00% | 0.0% |
| Q4 2022 | $392,785 | +44.4% | 5,096 | -16.7% | 0.00% | 0.0% |
| Q3 2022 | $272,000 | +38.1% | 6,116 | +19.4% | 0.00% | – |
| Q2 2022 | $197,000 | -16.9% | 5,121 | -6.1% | 0.00% | – |
| Q1 2022 | $237,000 | +9.2% | 5,453 | -4.8% | 0.00% | – |
| Q4 2021 | $217,000 | +11.3% | 5,730 | -2.9% | 0.00% | – |
| Q3 2021 | $195,000 | -30.1% | 5,901 | +42.3% | 0.00% | -100.0% |
| Q2 2021 | $279,000 | +47.6% | 4,147 | +24.6% | 0.00% | – |
| Q1 2021 | $189,000 | +33.1% | 3,328 | +90.9% | 0.00% | – |
| Q4 2020 | $142,000 | +6.8% | 1,743 | -6.7% | 0.00% | – |
| Q3 2020 | $133,000 | -39.3% | 1,869 | -30.0% | 0.00% | -100.0% |
| Q2 2020 | $219,000 | -21.8% | 2,669 | -43.9% | 0.00% | 0.0% |
| Q1 2020 | $280,000 | – | 4,759 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ALETHEA CAPITAL MANAGEMENT, LLC | 1,123,929 | $42,462,000 | 36.04% |
| MORGAN JESS S & CO INC | 114,525 | $4,327,000 | 2.66% |
| Fairmount Funds Management LLC | 187,598 | $7,087,000 | 2.34% |
| WMS Partners, LLC | 242,500 | $9,162,000 | 1.95% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 610,064 | $23,048,000 | 1.41% |
| MANGROVE PARTNERS IM, LLC | 400,000 | $15,112,000 | 0.90% |
| RTW INVESTMENTS, LP | 1,618,819 | $61,159,000 | 0.89% |
| MPM BioImpact LLC | 103,405 | $3,907,000 | 0.71% |
| Avidity Partners Management LP | 775,000 | $29,280,000 | 0.62% |
| FIRST MIDWEST BANK TRUST DIVISION | 115,028 | $4,346,000 | 0.56% |